📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.On May 12, 2026, The Lancet published the results of a 14-year global effort: Polycystic Ovarian Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). For over 170 million women worldwide — most of whom have never received a correct diagnosis — this is not just a nomenclature update. It is a reckoning.In this episode, Dr. Komal Patil-Sisodia breaks down what changed, what didn’t, and why the new name carries profound clinical implications across every hormonal era: adolescence, the reproductive years, perimenopause, and menopause and beyond. She connects the renaming to the 2026 ACC/AHA dyslipidemia guidelines, the 70% undiagnosis rate, and the lifelong metabolic consequences that the old name made invisible.If you’ve ever been handed a birth control pill without a workup, told your symptoms were stress, or felt dismissed in a clinical setting — this episode is for you.Timestamps00:00  Welcome to Clearly Hormonal  —  Dr. Patil-Sisodia introduces the podcast and her clinical background across endocrinology, internal medicine, obesity medicine, and menopause care.01:08  PCOS Gets Renamed  —  The official May 12, 2026 announcement in The Lancet: PCOS is now Polyendocrine Metabolic Ovarian Syndrome (PMOS). Why one letter — C to M — changes everything.02:38  Why the Old Name Hurt  —  The 14-year global process led by Professor Helena Teede involving 56 organizations and 22,000+ survey responses. How the word “polycystic” misdirected care for generations and contributed to delayed diagnosis, stigma, and fragmented treatment.04:32  Breaking Down PMOS  —  Word-by-word analysis: Polyendocrine (system-level hormonal disruption), Metabolic (insulin resistance, cardiovascular risk as core features, not side effects), Ovarian dysfunction (still present, but no longer the whole story).05:48  What Did Not Change  —  The Rotterdam diagnostic criteria remain intact. If you were diagnosed with PCOS, you have PMOS. Your clinical picture is valid. What changed is the language — and what that language demands of clinicians.07:19  Adolescence — The Era of Missed Beginnings  —  How PMOS manifests in teenage girls, why it gets dismissed as normal puberty, and what’s at stake when early insulin resistance goes untreated. The window to act — and how the new name changes what clinicians look for.10:37  Reproductive Years — The Era of Diagnosis and Distraction  —  Why PMOS is most often diagnosed in fertility contexts, and why that misses the metabolic picture. The connection to gestational diabetes, preeclampsia risk, and the 2026 ACC/AHA dyslipidemia guidelines.13:58  Perimenopause — The Era That Intensifies  —  How declining ovarian function accelerates metabolic dysfunction in women with PMOS. Why symptoms quiet in the 30s and return louder in the 40s. The urgent research questions the new name demands.17:16  Menopause and Beyond — The Era the Name Change Protects  —  Why post-menopausal women with PCOS/PMOS history face the highest cardiovascular risk of their lives — and why no one is connecting the dots. Lp(a), ApoB, and what to ask your clinician today.19:09  What the Name Actually Changes  —  A clinical summary: how each word in PMOS shifts the posture of care at every hormonal era. One name. Four eras. A completely different approach.20:56  Takeaways and Call to Action  —  What to do if you have a PMOS diagnosis, what to ask your clinician if you’re post-menopausal, and a message to clinicians: the name changed. Now the care has to change with it.What We CoverThe official renaming of PCOS to PMOS (Polyendocrine Metabolic Ovarian Syndrome) in The Lancet, May 2026Why the word “polycystic” was scientifically inaccurate and caused measurable clinical harmWhat each word in PMOS actually means clinicallyWhy 70% of people with this condition remain undiagnosed — and how framing drives that numberEra-by-era breakdown: adolescence, reproductive years, perimenopause, menopause and beyondThe 2026 ACC/AHA dyslipidemia guideline connection: PMOS as a cardiovascular risk enhancerLp(a) and ApoB: why Class 1 universal screening now matters for your PMOS historyWhat to ask your clinician at every stageResources MentionedThe Lancet PMOS Renaming Paper — May 12, 2026Professor Helena Teede, Monash University — lead researcherRotterdam Diagnostic Criteria for PMOS2026 ACC/AHA Dyslipidemia Guideline (PREVENT equations, Lp(a) universal screening, ApoB targets)The Endocrine Society — one of 56 organizations in the renaming processConnectInstagram: @drpatilsisodiaPodcast: Clearly HormonalPractice: eastsidemm.comIf this episode resonated, share it with a woman in your life who’s been searching for answers. Leave a review so more women can find this podcast.Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.